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Abstract
Background—Recent studies have identified chromosomal regions linked to variation in high
density lipoprotein cholesterol (HDL-C), apolipoprotein A-1 (Apo A-1) and triglyceride (TG),
although results have been inconsistent and previous studies of American Indian populations are
limited
Objective—In an attempt to localize quantitative trait loci (QTLs) influencing HDL-C, Apo A-1
and TG, we conducted genome-wide linkage scans of subjects of the Strong Heart Family Study.
Methods—We implemented analyses in 3484 men and women aged 18 years or older, at three
study centers.
Results—With adjustment for age, sex and center, we detected a QTL influencing both HDL-C
(LOD = 4.4, genome-wide P = 0.001) and Apo A-1 (LOD = 3.2, genome-wide P = 0.020) nearest
marker D6S289 at 6p23 in the Arizona sample. Another QTL influencing Apo A-1 was found
nearest marker D9S287 at 9q22.2 (LOD = 3.0, genome-wide P = 0.033) in the North and South
Dakotas. We detected a QTL influencing TG nearest marker D15S153 at 15q22.31 (LOD = 4.5 in
the overall sample and LOD = 3.8 in the Dakotas sample, genome-wide P = 0.0044) and when
additionally adjusted for waist, current smoking, current alcohol, current estrogen, lipid treatment,
impaired fasting glucose, and diabetes, nearest marker D10S217 at 10q26.2 (LOD = 3.7, genome-
wide P = 0.0058) in the Arizona population.
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Conclusions—The replication of QTLs in regions of the genome that harbor well-known
candidate genes suggest that chromosomes 6p, 9q and 15q warrant further investigation with fine
mapping for causative polymorphisms in American Indians.
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INTRODUCTION
High density lipoprotein cholesterol (HDL-C) and triglyceride (TG) concentrations are both
independent risk factors for cardiovascular disease (CVD).[1] Apolipoprotein A-1 (Apo
A-1), the major apoplipoprotein in HDL-C, is important for biochemical pathways that make
HDL-C antiatherogenic. It is estimated that each 1% increase in HDL-C concentration
reduces the risk of coronary heart disease by approximately 2% [2], although its etiologic
role has been debated, and that each 21% decrease in TG concentration reduces the risk of
non-fatal myocardial infarction and CVD death by 40% [3].
According to the Atlas of Heart Disease and Stroke among American Indians and Alaska
Natives [4], the age-adjusted prevalence of high blood cholesterol levels (>240 mg/dL)
(NCEP [1]) among American Indians living in 35 U.S. states was 30%, notably higher than
the approximately 17% prevalence [5] noted among the general United States (U.S.)
population. These prevalence measures do not differ significantly between female (29%)
and male (31%) American Indians. Similar, as for the prevalence of elevated HDL-C, data
from the Strong Heart Study (SHS), prevalence of low HDL-C levels (<40 mg/dL) was 34.2
– 36.7% among American Indian populations, and increased with age [6]. Another study
among an urban American Indian population demonstrated a strikingly high prevalence of
low HDL-C levels of 54.9% among males and of 54.2% among females [7], higher than the
general U.S. population (25.1% for males and 9.1% for females) [5]. This study also
reported 32.3% of males and 28.6% of females had high levels of triglycerides (≥ 150 mg/
dl) [7], similar to its prevalence in the general U.S. population (30%) [8].
Strong aggregate genetic effects on HDL-C, Apo A-1, and TG variability have been
recognized across multiple populations, although findings from candidate gene studies have
been conflicting. Nonetheless, recent genome-wide association studies (GWAS) have
identified several variants influencing HDL-C, Apo- A-1, and TG. For example, evidence
for association between HDL-C and several previously implicated lipid metabolism genes,
such as ABCA1 on chromosome (chr) 9 (rs4149268 [9], rs3890182 [10], and rs9282541
[11]) and LIPC on chr 15 (rs261332 and rs11858164 [11]) have been noted. In addition,
evidence for association between LIPC rs4775041 and TG and CETP rs1800775 on chr 16
and Apo A-1 concentrations [12] have been reported. Despite these exciting findings, much
of the heritable component of HDL-C, Apo-A1, and TG remains to be explained, suggesting
that other susceptibility variants are segregating in populations.
Genome-wide linkage scans have been performed to identify novel regions of the genome
harboring genes that regulate HDL-C, Apo A-1 and TG levels, but the identification of
quantitative trait loci (QTL) has been challenging. As with most common complex
phenotypes, several regions of the genome have been implicated, perhaps suggesting locus
heterogeneity. A genome-wide scan of HDL-C in a kindred with familial
hypercholesterolemia reported genome-wide significant linkage of HDL-C to chromosome 6
(LOD=3.1).[13]. Genome-wide significant linkage of Apo A-1 to chromosome 9q21.21-
q33.1 (LOD=3.28), 8p21.1-q13.1 (LOD=3.71) and 10p15.1-p13 (LOD=5.51).[14] Genome
wide significant evidence of linkage of TG to chromosome 4q28.3-32.1 (LOD=3.71) [14]
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and to chromosome 15 (LOD=3.88 at approximately 20–30 cM) [15] has been noted. Few
previous gene mapping studies of HDL-C, Apo A-1 and TG in American Indian populations
have been conducted.
More studies are necessary to advance our knowledge of the genetic factors influencing
HDL-C, Apo A-1 and TG, especially because genome-wide association studies have largely
been implemented in Caucasian samples. American Indians are an important United States
minority population that can inform knowledge in distinct ways due to their geographic and
genetic isolation and high rates of cardiovascular disease risk factors. For instance, because
of these qualities we may discover genetic variants that are unique to their genetic and
environmental context which can further our understanding of pathways to cardiovascular
disease. Further, replication of existing QTLs in independent samples is essential to
prioritize regions of the genome for costly comprehensive fine-mapping and ultimately
identification of functional variants. Thus, our objectives were to localize new QTLs
influencing HDL-C, Apo A-1, and TG as well as to provide new evidence in support of
previously identified QTLs by conducting a genome-wide scan in American Indian subjects
of the Strong Heart Family Study (SHFS).
MATERIALS AND METHODS
Study population
The SHFS is a multicenter, population-based, family study designed to localize genes that
influence risk factors for clinical and subclinical cardiovascular disease, diabetes, and
obesity and their progression over time. SHFS data were collected in two phases, the first
completed in 1999 and the second initiated in 2001. More than 3600 resident American
Indian tribal members aged 18 and older were recruited and examined in three study centers
in Arizona (AZ), North and South Dakota (ND/SD), and Oklahoma (OK). The SHFS
protocols were approved by the Indian Health Service Institutional Review Board, the
institutional review boards of the participating institutions, all participating communities
involved, and by all participants. All participants have given informed consent for the
genetic study of CVD and associated risk factors, including the present study. Detailed
descriptions of the SHFS protocols have been published.[16]
Phenotypic and genotypic data
Phenotypic data—Protocols for the collection of phenotypic data have been described
previously [17], and, briefly, are as follows. Fasting blood samples were obtained during a
physical examination and assayed at MedStar Research Institute using standard laboratory
methods [17]. TG, total cholesterol, HDL-C, and apolipoproteins were measured using
enzymatic reagents and the Hitachi 717. Glucose was measured by the hexokinase method
(Glucose-HK; BMD, Inc) on the Hitachi 717. Type II diabetes, impaired fasting glucose,
and normal glucose tolerance status were defined according to American Diabetes
Association criteria [18]. Waist circumference was measured with participants wearing light
clothing and without shoes. Information on demographic characteristics was obtained by
questionnaire. Ever smoking was defined as having had at least 100 cigarettes during ones
lifetime; current smoking was defined when participants answered “yes” to both of the
questions: whether they were current smokers and whether they had smoked more than 100
cigarettes in their life. Current and ever alcohol consumption were defined as having had at
least 12 alcoholic beverages in the last year (at least one day per month) and/or lifetime,
respectively. Reproductive history was queried including parity, gravidity, menopausal
status, and estrogen use.
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Genotypic data—The SHFS genotyping procedures have been documented previously
[19]. Specifically, DNA was isolated from fasting blood samples using organic solvents and
then amplified in separate PCR reactions with primers specific for short tandem repeat
markers using the ABI PRISM Linkage Mapping Set-MD10 version 2.5 (Applied
Biosystems, Foster City, CA). Paticipants were genotyped for approximately 400
microsatellite markers spaced at average 10 cM intervals (range, 2.4 to 24.1 cM) across the
autosomal chromosomes, with the average heterozygosity of these markers for 0.69 in the
Arizon subsample, 0.76 for the Dakotas, and 0.74 for Oklahoma. Analyses and assignment
of the marker alleles were done using electrophoresis and computerized algorithms (Applied
Biosystems). Sex-averaged chromosomal maps obtained from deCODE Genetics
(http://www.decodegenetics.com) were used. All genetic distances are reported in Haldane
centimorgans (cM). Pedigree relationships were verified using the PREST (Pedigree
Relationship Statistical Tests) package [20]. Mendelian inconsistencies and spurious double
recombinants were detected using the SimWalk2 package [21]. The overall blanking rate for
both types of errors was <1% of the total number of genotypes for Arizona, North and South
Dakota, and Oklahoma. We used web resources of the University of California Santa Cruz
(http://genome/ucsc.edu) and Online Mendelian Inheritance in Man
(http://www3.ncbi.nlm.nih.gov/entrez/query.fcgi?db 5 OMIM) to determine the cytogenetic
location of markers and to search for candidate genes.
Statistical analysis
Fasting plasma HDL-C and TG values were transformed by natural logarithm, and apo A-1
was transformed by dividing 1 by the apo A-1 value, because of their skewed distributions.
Multipoint variance component linkage analysis of ln(HDL-C), 1/(apo A-1) and ln(TG) was
performed among approximately 3,400 SHFS participants with complete covariate data
using SOLAR, version 2.1.4. Details of this model have been described previously.[22] The
use of the variance component approach requires an estimate of the identity-by-descent
matrices, which were computed using the Loki package [23] with a Markov chain Monte
Carlo stochastic procedure. Genome-wide p-values were obtained by the method of
Feingold et al. [24]
Stepwise linear regression was used to screen covariates for statistical significance using
SAS, version 9.1. Given the sensitivity of variance component analysis to kurtosis, all
phenotypic outliers of the trait of interest and all covariate data points (here defined as any
value ≥3 standard deviations from the mean) were removed before analysis (the number
excluded varies by variable; in all cases n < 30 or approximately 5% of the study
observations). To maximize our power to detect genetic effects, we considered two different
models of covariate adjustment in each population separately. In model 1, adjustments were
made for age, sex, and field center. In model 2, we additionally adjusted for waist
circumference, current smoking, current alcohol consumption, current estrogen use, lipid-
lowering treatment, diabetes status, and impaired fasting glucose. All analyses were also
run, and results reported, stratified by field center. Residuals were generated for both models
and used in all subsequent quantitative genetic analyses. Kurtosis values for ln(HDL-C), 1/
(apo A-1) and ln(TG) were <0.50 for all analyses.
RESULTS
Descriptive characteristics of the SHFS participants are summarized in Supplementary table
1. The average age ± SD of participants by center was ~37 ± 16, 39 ± 17, and 44 ± 17 years
in Arizona, Dakotas, and Oklahoma, respectively. Consistent with the results from our
previous studies of a subsample of these family members,[25] a high prevalence of current
cigarette smoking and alcohol consumption was observed. As expected, a high prevalence of
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diabetes was noted, especially in the Arizona center (32%). HDL-C, apo A-1 and TG
concentrations varied by center, where HDL-C was lowest in the Arizona population (48.52
±14 mg/dL), and apo A-1 (143.92 ± 27 mg/dL) and TG (163.59 ± 92 mg/dl) were highest in
Oklahoma. In contrast to many similarly-aged U.S. populations, we found a very low
prevalence of lipid-lowering therapy (≤ 6%).
Table 1 presents the multipoint genome-wide adjusted LOD scores and their locations from
the variance component linkage analyses of HDL-C, apo A-1 and TG for all linkage peaks
with LOD scores ≥1.8 [suggestive evidence for linkage [26]]. A QTL for HDL-C (adjusted
LOD=4.4, genome-wide P =0.001) was detected in the Arizona population on chromosome
6p23 at 36 cM, nearest marker D6S289 (fig 1). The 1-cM LOD unit support interval spanned
12 cM, from 29 to 41 cM (10.033–20.578 Mb P terminus), between marker D6S470 and
D6S422. Upon adjustment for multiple confounders (model 2), the magnitude of LOD score
decreased by 1.6 units, yet suggestive evidence for linkage was still noted (LOD =2.8,
genome-wide P =0.054).
Further suggestive evidence of linkage to HDL-C level was observed in the North and South
Dakotas population on chromosome 9q31.1-q31.3 at 110 cM (LOD=1.9) between D9S1690
and D9S167, and in the Oklahoma population on chromosome 9q22.2-q31.1 at 101 cM
(LOD=2.1), close to marker D9S287. In addition, we found suggestive evidence of linkage
to HDL-C in the Oklahoma population at 193 cM on chromosome 3q26.31-q27.3
(LOD=1.9), nearest marker D3S1262.
Genome-wide significant evidence of linkage to apo A-1 levels was detected in the Arizona
population on chromosome 6p23 (LOD = 3.2, genome-wide P = 0.020) at 36 cM, nearest
marker D6S289 (fig 2). The 1-cM LOD unit support interval spanned 10 cM, from 31 to 41
cM (10.033–20.578 Mb P terminus), between markers D6S470 and D6S422. Upon
adjustment for multiple confounders (model 2), the magnitude of the LOD score decreased
by 1.1 units, yet suggestive evidence for linkage was still noted (LOD =2.1). We also
detected genome wide significant linkage to apo A-1 levels in the North and South Dakotas
population on chromosome 9q22.2 at 99 cM (LOD = 3.0, genome-wide P = 0.033), nearest
marker D9S287 (fig 3). The 1-cM LOD unit support interval spanned 22 cM from 90 to 112
cM (84.873–111.077 Mb q terminus), between D9S167 and D9S1677.
Further suggestive evidence of linkage to apo A-1 level was observed in the North and
South Dakotas population on chromosome 2q33.3-q35 at 214 cM (LOD=2.2), nearest
marker D2S2382, on chromosome 9q22.2-q31.1 at 103 cM (LOD=2.5) between D9S287
and D9S1690 and on chromosome 12q24.32 at 162 cM (LOD=2.1), close to marker
D12S1659, and in the Oklahoma population on chromosome 7q21.11-q21.13 at 92 cM
(LOD=1.9), nearest marker D7S669 (table 1).
Genome-wide significant evidence of linkage to TG levels was detected in the North and
South Dakotas population on chromosome 15q22.31 (LOD = 3.8, genome-wide P =0.0044)
at 68 cM, nearest marker D15S153 (fig 4). The 1-cM LOD unit support interval spanned 15
cM from 61 to 76 cM (56.166–69.071 Mb q terminus), between D15S117 and D15S131.
When excluding participants on lipid lowering therapy, this LOD score increased to 5.0
(data not shown). We also detected genome wide significant linkage to TG levels in the
Arizona population on chromosome 10q26.2 at 164 cM (LOD = 3.7, genome-wide P
=0.0058), nearest marker D10S217 (fig 5). This LOD score was slightly lower when
adjustments were made for age and sex only (model 1) (LOD = 2.9, genome-wide P
=0.042). The 1-cM LOD unit support interval spanned 11 cM from 156 to 167 cM
(125.078–129.530 Mb q terminus), between D10S587 and D10S217.
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Suggestive evidence of linkage to TG levels was detected in the Arizona population on
chromosome 4q32.3-q34.1 at 168 and 169 cM between D4S1597 and D4S1539, on
chromosome 6p12.1-q14.1 at 87 cM, between D6S257 and D6S460, on chromosome
15q15.1-q21.1 at 44 cM, close to D15S994, and on chromosome 18p11.21-q12.1 at 40 cM,
near D18S53. In the Oklahoma population, suggestive evidence of linkage to TG levels was
noted at 67 cM on chromosome 11q12.1-q13.2 between D11S4191 and D11S987, and at 10
cM on chromosome 21q21.1, near D21S1899 (table 1).
DISCUSSION
The present study was conducted to identify regions of the genome harboring genes that
influence HDL-C, Apo A-1 and TG levels in large extended American Indian families.
Here, we present evidence for a QTL for HDL-C and apo A-1 levels in the Arizona
population on chromosome 6p nearest marker D6S289, and for apo A-1 levels in the North
and South Dakotas population on chromosome 9 nearest marker D9S287 at 9q22.2. We also
detected significant QTLs for TG levels in the North and South Dakotas population on
chromosome 15 nearest marker D15S153, and in the Arizona population on chromosome
10, nearest marker D10S217 at 10q26.2.
Chromosome 6p, where we observe our strongest linkage evidence for HDL-C and apo A-1,
has previously been implicated in four genome scans of lipid-related traits.[13, 27–29]
Genome-wide significant LOD scores were reported in this region for HDL-C in a kindred
with familial hypercholesterolemia (LOD=3.1) [13]. Suggestive linkage has also been noted
for total apoB in French-Canadian families (LOD=1.35) [29] and in French-Canadian
families (LOD=1.32) [28]. The strongest positional candidate genes are located ~4Mb from
our highest LOD score, the ELOVL2 and TFAP2A genes. Cell over-expression of ELOVL2
gene, encoding a polyunsaturated fatty acid elongase, enhances TG synthesis and
accumulation of lipid droplets [30]. TFAP2A (transcription factor AP-2 alpha) encodes the
activator protein (AP)2α and negatively regulates ABCA1 promoter activity [31]. However,
to date no previous studies have examined whether ELOVL2 or TFAP2A polymorphisms
influence variation in HDL-C or apo A-1. The same QTL detected for both HDL-C and apo
A-1 is consistent with the biological structure for apo A-1, the major structural protein of
HDL-C.
To further support our results on 6p, we evaluated the P-values from the association between
SNP genotypes and HDL-C, apo A-1 and TG concentrations for SNPs within or in LD with
biological candidate genes underlying the 1 LOD support interval of our linkage peak on 6p
among approximately 2,600 participants of the Diabetes Genetic Initiative (DGI) study
(available at http://www.broad.mit.edu/diabetes/). Of the 1,870 SNPs within the 1-cM LOD
unit support interval on chromosome 6p, evidence for association with HDL-C was observed
for ELOVL2 SNP rs3798712 (P =0.0147), and evidence for association with apo A-1 was
observed for ELOVL2 SNP rs3798712 (P =0.0032) and TFAP2A SNP rs12663250 (P
=0.0214) (Supplementary table 2).
We also attempted to support our results on 6p using GWAS data from 1087 participants of
the offspring cohort of the Framingham Heart Study (FHS) SHARe 100K online resource.
All results for autosomal SNPs are available through NCBI dbGaP
(http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007). We examined
if any SNP with a P-value ≤ 0.05 was located within a candidate gene for HDL-C, apo A-1
or TG or tagged a candidate gene under our genome wide significant linkage peaks. No
evidence for association was observed among the FHS offspring cohort.
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Chromosome 9q, where we observe our strongest linkage evidence for Apo A-1 levels, has
previously been implicated in six genome scans of lipid-related traits. [9, 14, 32–35]
Genome-wide significant LOD scores were reported in this region for Apo A-1 (LOD=3.28)
in female sib-pairs [14]. The strongest positional candidate gene is located ~9 Mb from our
highest LOD score, the ABCA1 gene. The ATP-binding cassette (ABC) protein encoded by
this gene functions as a cholesterol efflux pump in the cellular lipid removal pathway, with
cholesterol as its substrate. One study showed an association between apo A-1 levels and
ABCA1 14C>T polymorphisms in a Malay population (ORTT/CC=2.92, 95%CI=1.42–6.00;
ORCT/CC=1.29, 95%CI=0.81–2.04).[36]
It is notable that ABCA1 is a rate-limiting factor for HDL-C biogenesis. Indeed, GWAS
study findings also support an association between ABCA1 variants and HDL-C, for
example, rs9282541 (−3.2 mmol/L decrease per T allele, P = 3.2 × 10−5) [11] and rs4149274
(1.51 mg/dL increase per G allele, P ~ 7.4 × 10−8) [9]. On-line GWAS resources further
support the association with ABCA1 gene variants. Eight SNPs of the ABCA1 gene within
the 1-cM LOD unit support interval of chromosome 9q, were associated with apo A-1
(P≤0.05) in white participants of the DGI study (Supplementary table 2). In contrast, no
evidence for this association was observed among the FHS offspring cohort (all P > 0.05).
Chromosome 15q, where we observe our strongest linkage evidence for TG levels, has
previously been implicated in four genome scans of lipid-related traits.[37–40] Genome-
wide significant LOD scores were reported in this region for TG and HDL-C levels among
participants from NHLBI Family Heart study project (LOD=3.0), for HDL-C (LOD=3.3)
among Mexican American individuals from the San Antonio Family Heart Study project
[40], and for HDL-C among participants from the Genetic Epidemiology of Metabolic
Syndrome project (LOD=3.1) [38]. Suggestive linkage has also been noted for TG in family
members with familial hypertriglyceridemia (LOD=1.35).[37] Approximately 587 genes
underlie the 1 LOD unit support interval (46 cM, 45.2 Mb) of the 15q signal. The strongest
positional candidate gene is located ~8Mb from our highest LOD score, the LIPC gene.
LIPC (hepatic triglyceride lipase) is a lipolytic enzyme that has dual functions of triglyceride
hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake [41]. Recent
data show inconsistent results in the association between LIPC polymorphisms and TG
variation [42, 43] and between LIPC and HDL and LDL concentrations [27, 44]. A recent
GWAS study [9] identified a significant association between TG and LIPC SNP rs4775041
(3.62 mg/dL increase per C allele combined P = 1.6 × 10−8). With respect to the on-line DGI
GWAS resource, of the 5,844 SNPs on chromosome 15q within the 1-cM LOD unit support
interval, nine SNPs within the LIPC gene were associated with TG (P≤0.05) (Supplementary
table 2). With respect to the Framingham 100K GWAS resource, LIPC SNPs, rs2899632 (P
= 0.0032) and rs8028759 (P = 0.02) were associated with TG measured at FHS
Examinations 7 and 4, respectively.
Significant linkage of TG levels to chromosome 10q has also been reported in several other
studies. Pajukanta et al [45] studied Finnish families with familial combined hyperlipidemia
and found a LOD of 2.6 for cholesterol at the same location on chromosome 10.
Approximately 33 known genes underlie the 1 LOD unit support interval (12 cM, 4.5 Mb) of
the 10q signal. However, this chromosome 10q locus is in a region lacking any obvious
positional candidate genes with known functions related to lipid metabolism, suggesting that
this locus may harbor a novel lipid gene.
We also observed several loci with suggestive linkage to HDL-C, apo A-1 and TG, some
novel and others supporting positive findings from other studies. Supplementary table 3
summarizes the observed linkage signals from this study that are supported by evidence of
linkage to lipid-related traits in other populations on 2q, 3q, 4q, 7q, 11q, 12q, 18, and 21q.
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Although these signals do not meet the genome-wide significance threshold, these results
still offer valuable information in that they may identify regions worthy of further study.
We found that when excluding American Indian participants on lipid lowering therapy (n =
66 participants in the Dakotas center), the magnitude of the LOD score for TG on
chromosome 15q increased by 1.2 units (adjusted LOD =5.0). We can offer several possible
explanations for these findings. First, as lipid-lowering medications may lower the
concentration of TG [46], the TG values of these medicated subjects may not accurately
reflect their true values. Secondly, it is possible that by excluding medicated individuals
from the analysis, the genetic locus heterogeneity was reduced, thereby strengthening the
evidence for linkage at this particular QTL. When additionally adjusting TG for waist
circumference, current smoking status, current consumption of alcohol, current estrogen use,
lipid-lowering treatment status, and diabetes status, the magnitude of the LOD score on
chromosome 10q increased by 1.6 units (LOD =3.7). As the sample of examined individuals
remained the same, we infer that by reducing the residual covariate effects (model 1 with
only adjustment for sex and age), we had greater power to detect a QTL specific effect at
this locus on chromosome 10q. As no other modifications (amplifications or attenuations) of
LOD scores were noted upon adjustment for lipid lowering therapies and the percentage of
participants taking lipid lowering drugs was low, we report both findings that have been
adjusted for lipid lowering therapy and those that did not.
In conclusion, our findings suggest that one or more genes on chromosomes 6 and 9 regulate
HDL cholesterol and apopliprotein A-1 concentrations, and on chromosomes 10 and 15
regulate triglyceride concentrations. Excellent candidate genes are implicated in each of
these genomic regions and future research should pursue these positional candidate genes,
particularly for the ELOV2, the ABCA1 and the LIPC genes, to determine whether
polymorphisms in these genes are the source of these highly replicated linkage signals. Our
study also provides corroboration of genomic regions that possibly influence interindividual
variation in HDL-C, apo A-1 and TG concentrations on chromosome 2, 3, 4, 7, 9, 12, and
18, and new information about genomic regions on 11 and 21. The identification and
confirmation of QTLs for HDL-C, apo A-1 and TG concentrations may bring us closer to
the identification of the functional genes that influence these phenotypes and aid in the
targeting of preventative therapies for individuals with low circulating levels of HDL-C and
apo A-1, and high fasting triglyceride concentrations, established risk factors for CVD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• More studies are necessary to advance our knowledge of the genetic factors
influencing HDL-C, Apo A-1 and TG among US minority populations,
particularly American Indians which can inform knowledge in distinct ways due
to their geographic and genetic isolation and high rates of cardiovascular disease
risk factors.
• In this study, four QTLs influencing HDL-C, apo A-1 , and TG levels were
identified in the American Indian participants of the Strong Heart Family Study,
on chromosomes 6p, 9q, 15q, and 10q.
• These signals implicate excellent candidate genes, particularly for the ELOV2,
the ABCA1 and the LIPC genes, and are supported by several linkage and
association studies across multiple ethnic groups, suggesting a generalization of
lipid related genetic effects across multiple populations.
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Multipoint LOD scores on chromosome 6 for HDL cholesterol. Results for combined and
stratified analyses shown. Model 1 was adjusted for age, sex, and field center (combined
analysis). Model 2 was additionally adjusted for waist circumference, current smoking
status, current alcohol consumption, current estrogen use, lipid treatment status, impaired
fasting glucose and diabetes status. AZ, Arizona field center; DA, Dakotas field centers;
OK, Oklahoma field center; cM, Haldane centimorgans.
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Multipoint LOD scores on chromosome 6 for apolipoprotein A-I. Results for combined and
stratified analyses shown. Model 1 was adjusted for age, sex, and field center (combined
analysis). Model 2 was additionally adjusted for waist circumference, current smoking
status, current alcohol consumption, current estrogen use, lipid treatment status, impaired
fasting glucose and diabetes status. AZ, Arizona field center; DA, Dakotas field centers;
OK, Oklahoma field center; cM, Haldane centimorgans.
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Multipoint LOD scores on chromosome 9 for apolipoprotein A-I. Results for combined and
stratified analyses shown. Model 1 was adjusted for age, sex, and field center (combined
analysis). Model 2 was additionally adjusted for waist circumference, current smoking
status, current alcohol consumption, current estrogen use, lipid treatment status, impaired
fasting glucose and diabetes status. AZ, Arizona field center; DA, Dakotas field centers;
OK, Oklahoma field center; cM, Haldane centimorgans.
Li et al. Page 16














Multipoint adjusted LOD scores on chromosome 15 for triglycerides. Results for combined
and stratified analyses shown. Model 1 was adjusted for age, sex, and field center (combined
analysis). Model 2 was additionally adjusted for waist circumference, current smoking
status, current alcohol consumption, current estrogen use, lipid treatment status, impaired
fasting glucose and diabetes status. AZ, Arizona field center; DA, Dakotas field centers;
OK, Oklahoma field center; cM, Haldane centimorgans.
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Multipoint adjusted LOD scores on chromosome 10 for triglycerides. Results for combined
and stratified analyses shown. Model 1 was adjusted for age, sex, and field center (combined
analysis). Model 2 was additionally adjusted for waist circumference, current smoking
status, current alcohol consumption, current estrogen use, lipid treatment status, impaired
fasting glucose and diabetes status. AZ, Arizona field center; DA, Dakotas field centers;
OK, Oklahoma field center; cM, Haldane centimorgans.
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